Investors

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson’s Disease (PD).

Stock Snapshot

BCLI (Common Stock) $3.48 - 0.03 (0.85%)

Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

Upcoming Events

Email Alerts
Investor Contact
Investor FAQs
RSS Feeds